JP2021527713A5 - - Google Patents
Info
- Publication number
- JP2021527713A5 JP2021527713A5 JP2021519532A JP2021519532A JP2021527713A5 JP 2021527713 A5 JP2021527713 A5 JP 2021527713A5 JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021519532 A JP2021519532 A JP 2021519532A JP 2021527713 A5 JP2021527713 A5 JP 2021527713A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- markers
- proliferative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024109073A JP2024153667A (ja) | 2018-06-15 | 2024-07-05 | 増殖性細胞を抑制する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862685866P | 2018-06-15 | 2018-06-15 | |
| US62/685,866 | 2018-06-15 | ||
| PCT/US2019/037559 WO2019241802A2 (en) | 2018-06-15 | 2019-06-17 | Methods of inhibiting proliferative cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024109073A Division JP2024153667A (ja) | 2018-06-15 | 2024-07-05 | 増殖性細胞を抑制する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527713A JP2021527713A (ja) | 2021-10-14 |
| JP2021527713A5 true JP2021527713A5 (https=) | 2022-06-27 |
Family
ID=67138135
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519532A Pending JP2021527713A (ja) | 2018-06-15 | 2019-06-17 | 増殖性細胞を抑制する方法 |
| JP2024109073A Pending JP2024153667A (ja) | 2018-06-15 | 2024-07-05 | 増殖性細胞を抑制する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024109073A Pending JP2024153667A (ja) | 2018-06-15 | 2024-07-05 | 増殖性細胞を抑制する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210371855A1 (https=) |
| EP (1) | EP3806850A2 (https=) |
| JP (2) | JP2021527713A (https=) |
| WO (1) | WO2019241802A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020013120A (es) | 2018-06-04 | 2021-07-21 | Broad Inst Inc | Tratamiento terapéutico de cánceres de microsatélites inestables. |
| JP7714162B6 (ja) * | 2018-12-03 | 2025-09-08 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法 |
| AR122534A1 (es) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3 |
| KR20230160268A (ko) * | 2021-02-25 | 2023-11-23 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 프로그래밍 가능한 단백질 분해용 화합물 및 질환 치료를 위한 사용 방법 |
| UY39786A (es) * | 2021-05-26 | 2023-01-31 | Novartis Ag | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades |
| WO2023062575A1 (en) * | 2021-10-14 | 2023-04-20 | Ideaya Biosciences, Inc. | Cyclic vinyl sulfone compounds as wrn inhibitors |
| KR20250034120A (ko) * | 2022-07-06 | 2025-03-10 | 비비디온 테라퓨틱스, 인코포레이티드 | Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물 |
| US20240197715A1 (en) | 2022-11-18 | 2024-06-20 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024140597A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州浦合医药科技有限公司 | Wrn解旋酶抑制剂 |
| WO2024153155A1 (zh) * | 2023-01-18 | 2024-07-25 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| WO2024153244A1 (zh) * | 2023-01-20 | 2024-07-25 | 南京再明医药有限公司 | 含氮类化合物 |
| EP4695240A2 (en) * | 2023-04-11 | 2026-02-18 | Nimbus Wadjet, Inc. | Cyclic vinyl sulfone wrn inhibitors |
| WO2024235844A1 (en) * | 2023-05-12 | 2024-11-21 | Institut National de la Santé et de la Recherche Médicale | Methods of preventing on-target genotoxicity induced by nucleases |
| TW202510857A (zh) * | 2023-06-01 | 2025-03-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 化合物及其用途 |
| CN121666389A (zh) * | 2023-08-01 | 2026-03-13 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025106693A1 (en) * | 2023-11-16 | 2025-05-22 | Eikon Therapeutics, Inc. | Methods and compositions for treating cancers with high microsatellite instability levels |
| WO2025131978A1 (en) * | 2023-12-20 | 2025-06-26 | Nerviano Medical Sciences S.R.L. | Drug-linker reagents for conjugation |
| WO2025239377A1 (ja) * | 2024-05-16 | 2025-11-20 | 株式会社ジーンケア研究所 | ＷＲＮヘリカーゼ遺伝子を標的とするｓｉＲＮＡ |
| WO2025237361A1 (zh) * | 2024-05-16 | 2025-11-20 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025252190A1 (en) * | 2024-06-07 | 2025-12-11 | Cullgen Inc. | Targeted degraders of werner syndrome recq helicase |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372772B1 (en) * | 1997-08-01 | 2002-04-16 | Prolx Pharmaceuticals Corporation | Inhibitors of redox signaling and methods of using same |
| CA2423192C (en) * | 2000-09-20 | 2010-11-23 | Karolinska Innovations Ab | 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
| US6448080B1 (en) * | 2001-02-23 | 2002-09-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of WRN expression |
| DE60306896T2 (de) * | 2002-02-21 | 2007-02-15 | Aprea Ab | Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen |
| CN1965076B (zh) * | 2004-05-19 | 2011-01-26 | 波士顿大学理事会 | 由wrn介导端粒引发的细胞信号传导的调节 |
| CA2769038A1 (en) * | 2009-07-31 | 2011-02-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Antiangiogenic small molecules and methods of use |
| JP5762103B2 (ja) * | 2011-04-13 | 2015-08-12 | 国立大学法人滋賀医科大学 | 頭頸部癌及び食道癌用抗癌剤及び増強剤 |
| CA2869729C (en) * | 2012-04-10 | 2021-12-28 | Vib Vzw | Novel markers for detecting microsatellite instability in cancer and determining synthetic lethality with inhibition of the dna base excision repair pathway |
| EP3007705A4 (en) * | 2013-06-12 | 2017-02-15 | Oncoimmunin, Inc. | Systemic in vivo delivery of oligonucleotides |
| AU2017286835B2 (en) | 2016-06-29 | 2023-12-14 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
| US11530413B2 (en) * | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| MX2020013120A (es) * | 2018-06-04 | 2021-07-21 | Broad Inst Inc | Tratamiento terapéutico de cánceres de microsatélites inestables. |
| UY39786A (es) * | 2021-05-26 | 2023-01-31 | Novartis Ag | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades |
-
2019
- 2019-06-17 EP EP19735074.7A patent/EP3806850A2/en not_active Withdrawn
- 2019-06-17 JP JP2021519532A patent/JP2021527713A/ja active Pending
- 2019-06-17 US US17/252,430 patent/US20210371855A1/en not_active Abandoned
- 2019-06-17 WO PCT/US2019/037559 patent/WO2019241802A2/en not_active Ceased
-
2024
- 2024-07-05 JP JP2024109073A patent/JP2024153667A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527713A5 (https=) | ||
| Di Carlo et al. | State of the art CRISPR-based strategies for cancer diagnostics and treatment | |
| Dobbelstein et al. | Targeting tumour-supportive cellular machineries in anticancer drug development | |
| Schneider et al. | Tissue-specific tumorigenesis: context matters | |
| Moffat et al. | Discovery of 2-(6-{[(6-fluoroquinolin-2-yl) methyl] amino} bicyclo [3.1. 0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor | |
| JP2021526133A5 (https=) | ||
| EP3691620B1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| JP2021526132A5 (https=) | ||
| EP3655004A2 (en) | Compositions and methods to treat cancer | |
| JP2020522508A5 (https=) | ||
| CN110582581A (zh) | 用于治疗过度增殖性疾病的方法中的atr激酶的抑制剂 | |
| JP2020516693A5 (https=) | ||
| Boyle et al. | Targeting DNA mismatches with rhodium metalloinsertors | |
| Jaiswal et al. | DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer | |
| Serda et al. | Glycofullerenes as non-receptor tyrosine kinase inhibitors-towards better nanotherapeutics for pancreatic cancer treatment | |
| Couto et al. | Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines | |
| JP2025526644A5 (https=) | ||
| Nabilsi et al. | Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter | |
| Chen et al. | The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells | |
| JP2011524355A5 (https=) | ||
| JP2021514979A5 (https=) | ||
| US9801854B1 (en) | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer | |
| JP2022507265A5 (https=) | ||
| JP2016519084A5 (https=) | ||
| Shukla et al. | Genetics and epigenetics of lung cancer: mechanisms and future perspectives |